Top-Rated Stocks NYSE:PEN Penumbra - PEN Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Penumbra, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $274.67 -3.15 (-1.13%) (As of 03/24/2023 12:00 AM ET) Add Compare Share Share Today's Range$272.61▼$278.3450-Day Range$233.13▼$277.8252-Week Range$114.86▼$283.42Volume307,102 shsAverage Volume381,578 shsMarket Capitalization$10.49 billionP/E RatioN/ADividend YieldN/APrice Target$265.42 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Penumbra MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside3.4% Downside$265.42 Price TargetShort InterestBearish11.65% of Float Sold ShortDividend StrengthN/ASustainability-1.25Upright™ Environmental ScoreNews Sentiment0.68Based on 6 Articles This WeekInsider TradingSelling Shares$7.04 M Sold Last QuarterProj. Earnings Growth82.95%From $1.29 to $2.36 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.06 out of 5 starsMedical Sector548th out of 1,005 stocksSurgical & Medical Instruments Industry55th out of 102 stocks 2.5 Analyst's Opinion Consensus RatingPenumbra has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 13 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $265.42, Penumbra has a forecasted downside of 3.4% from its current price of $274.67.Amount of Analyst CoveragePenumbra has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 0.0 Short Interest Percentage of Shares Shorted11.65% of the float of Penumbra has been sold short.Short Interest Ratio / Days to CoverPenumbra has a short interest ratio ("days to cover") of 12.3, which indicates bearish sentiment.Change versus previous monthShort interest in Penumbra has recently increased by 3.98%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldPenumbra does not currently pay a dividend.Dividend GrowthPenumbra does not have a long track record of dividend growth. Previous Next 3.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScorePenumbra has received a 47.10% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Surgical instruments" product. See details.Environmental SustainabilityThe Environmental Impact score for Penumbra is -1.25. Previous Next 3.2 News and Social Media Coverage News SentimentPenumbra has a news sentiment score of 0.68. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Penumbra this week, compared to 3 articles on an average week.Search Interest15 people have searched for PEN on MarketBeat in the last 30 days. This is an increase of 7% compared to the previous 30 days.MarketBeat Follows4 people have added Penumbra to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Penumbra insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,035,065.00 in company stock.Percentage Held by InsidersOnly 5.50% of the stock of Penumbra is held by insiders.Percentage Held by Institutions82.42% of the stock of Penumbra is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Penumbra are expected to grow by 82.95% in the coming year, from $1.29 to $2.36 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Penumbra is -4,577.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Penumbra is -4,577.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPenumbra has a P/B Ratio of 10.44. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Penumbra (NYSE:PEN) StockPenumbra, Inc. engages in the design, development, manufacture, and marketing of innovative medical devices. It offers neurovascular thrombectomy and embolization and access technologies, neurosurgical tools, Penumbra LANTERN Delivery Microcatheter, and Penumbra Occlusion Device (POD) system. The company was founded by Arani Bose and Adam Elsesser on June 21, 2004, and is headquartered in Alameda, CA.Read More Receive PEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Penumbra and its competitors with MarketBeat's FREE daily newsletter. Email Address PEN Stock News HeadlinesMarch 10, 2023 | marketbeat.comAre These Medical Device Makers Getting Ready To Rally? (PEN)Current trends and changing demographics are behind growth of medical technology companies. An aging population and a shift to in-home care are among factors.March 24, 2023 | americanbankingnews.comPenumbra, Inc. (NYSE:PEN) Given Consensus Recommendation of "Moderate Buy" by AnalystsMarch 26, 2023 | Legacy Research (Affiliate) (Ad)"Prepare for Five Years of Famine"Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecastMarch 20, 2023 | americanbankingnews.comPenumbra, Inc. (NYSE:PEN) Director Sells $223,107.50 in StockMarch 11, 2023 | finance.yahoo.comReturns On Capital Are Showing Encouraging Signs At Penumbra (NYSE:PEN)March 8, 2023 | finance.yahoo.comWhy Penumbra CEO Adam Elsesser Says It's Going To Be 'The Most Extraordinary Year'February 24, 2023 | finance.yahoo.comPenumbra (PEN) Q4 Earnings Top Estimates, Sales Remain RobustFebruary 24, 2023 | finance.yahoo.comQ4 2022 Penumbra Inc Earnings CallMarch 26, 2023 | Oxford Club (Ad)My No. 1 dividend stock for a LIFETIME of income.Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century! I think it's a crying shame folks don't know how powerful dividends are.February 23, 2023 | finance.yahoo.comPenumbra (PEN) Q4 Earnings and Revenues Surpass EstimatesFebruary 23, 2023 | finance.yahoo.comPenumbra, Inc. Reports Fourth Quarter and Full Year 2022 Financial ResultsFebruary 22, 2023 | finance.yahoo.comShould You Buy Penumbra (PEN) Ahead of Earnings?February 16, 2023 | finance.yahoo.comPenumbra, Inc. to Present at Citi's 2023 Healthcare Services, Medtech, Tools & HCIT ConferenceJanuary 29, 2023 | finance.yahoo.comInvesting in Penumbra (NYSE:PEN) five years ago would have delivered you a 160% gainJanuary 26, 2023 | finance.yahoo.comPenumbra, Inc. Schedules Fourth Quarter and Full Year 2022 Earnings Release and Conference Call for February 23, 2023January 16, 2023 | marketwatch.comNeurology Devices Market With Highly Productive Segment To Expand Outstandingly | Including 94 Pages ReportJanuary 10, 2023 | finance.yahoo.comPENUMBRA LAUNCHES LATEST INNOVATION IN MECHANICAL THROMBECTOMY: LIGHTNING FLASH™December 19, 2022 | finance.yahoo.comPenumbra, Inc. to Present at the 41st Annual J.P. Morgan Healthcare ConferenceNovember 28, 2022 | msn.comHoliday Arts Guide: From Santa to Scrooge, there are plenty of seasonal stage offeringsNovember 15, 2022 | finance.yahoo.comPenumbra Launches First Hands-Free, Full Body Virtual Reality-Based Offering for Rehabilitation, Expanding REAL® System PlatformNovember 9, 2022 | finance.yahoo.comPenumbra Third Quarter 2022 Earnings: EPS Beats ExpectationsNovember 4, 2022 | finance.yahoo.comPenumbra's Lightning Flash Launch Pushed Into Next Year, Trims FY22 ForecastsNovember 3, 2022 | finance.yahoo.comPenumbra (PEN) Tops Q3 Earnings and Revenue EstimatesOctober 19, 2022 | finance.yahoo.comGlobal Thrombectomy Devices Market Research Report 2021-2032 - Yahoo FinanceOctober 13, 2022 | washingtonpost.comMosaic Theater's 'Till Trilogy' arrives with uncanny timeliness - The Washington PostOctober 12, 2022 | benzinga.comWhat 8 Analyst Ratings Have To Say About Penumbra - Penumbra (NYSE:PEN) - BenzingaOctober 10, 2022 | finance.yahoo.comWhy Celsius Doxxed Hundreds of Thousands of Users - Yahoo FinanceSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive PEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Penumbra and its competitors with MarketBeat's FREE daily newsletter. Email Address PEN Company Calendar Last Earnings2/23/2023Today3/26/2023Next Earnings (Estimated)5/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNYSE:PEN CUSIPN/A CIK1321732 Webwww.penumbrainc.com Phone(510) 748-3200Fax510-748-3232Employees3,900Year FoundedN/APrice Target and Rating Average Stock Price Forecast$265.42 High Stock Price Forecast$303.00 Low Stock Price Forecast$185.00 Forecasted Upside/Downside-3.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)($0.06) Trailing P/E RatioN/A Forward P/E Ratio212.92 P/E GrowthN/ANet Income$-2,000,000.00 Net Margins-0.24% Pretax Margin0.46% Return on Equity0.66% Return on Assets0.48% Debt Debt-to-Equity Ratio0.02 Current Ratio5.21 Quick Ratio2.91 Sales & Book Value Annual Sales$847.13 million Price / Sales12.38 Cash Flow$0.80 per share Price / Cash Flow343.65 Book Value$26.30 per share Price / Book10.44Miscellaneous Outstanding Shares38,180,000Free Float36,079,000Market Cap$10.49 billion OptionableOptionable Beta0.52 Key ExecutivesAdam ElsesserChairman, President & Chief Executive OfficerBen SorciExecutive Vice President-OperationsMaggie S. YuenChief Financial OfficerPankaj TiwariChief Information Officer & Executive VPCorey L. TeigenChief Scientific OfficerKey CompetitorsTeleflexNYSE:TFXShockwave MedicalNASDAQ:SWAVInspire Medical SystemsNYSE:INSPStevanato GroupNYSE:STVNNovoCureNASDAQ:NVCRView All CompetitorsInsiders & InstitutionsHarpreet GrewalSold 875 sharesTotal: $223,107.50 ($254.98/share)Victory Capital Management Inc.Sold 4,443 shares on 3/10/2023Ownership: 0.086%Johanna RobertsSold 600 sharesTotal: $155,172.00 ($258.62/share)Harpreet GrewalSold 710 sharesTotal: $184,230.80 ($259.48/share)Voya Investment Management LLCBought 20,679 shares on 2/28/2023Ownership: 0.341%View All Insider TransactionsView All Institutional Transactions PEN Stock - Frequently Asked Questions Should I buy or sell Penumbra stock right now? 13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Penumbra in the last twelve months. There are currently 13 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PEN shares. View PEN analyst ratings or view top-rated stocks. What is Penumbra's stock price forecast for 2023? 13 Wall Street analysts have issued 1 year price objectives for Penumbra's stock. Their PEN share price forecasts range from $185.00 to $303.00. On average, they anticipate the company's stock price to reach $265.42 in the next year. This suggests that the stock has a possible downside of 3.4%. View analysts price targets for PEN or view top-rated stocks among Wall Street analysts. How have PEN shares performed in 2023? Penumbra's stock was trading at $222.46 at the start of the year. Since then, PEN stock has increased by 23.5% and is now trading at $274.67. View the best growth stocks for 2023 here. When is Penumbra's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 2nd 2023. View our PEN earnings forecast. How were Penumbra's earnings last quarter? Penumbra, Inc. (NYSE:PEN) released its earnings results on Thursday, February, 23rd. The company reported $0.16 earnings per share for the quarter, beating the consensus estimate of $0.14 by $0.02. The company had revenue of $221.22 million for the quarter, compared to analysts' expectations of $217.03 million. Penumbra had a positive trailing twelve-month return on equity of 0.66% and a negative net margin of 0.24%. The firm's quarterly revenue was up 8.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.10 EPS. What ETFs hold Penumbra's stock? ETFs with the largest weight of Penumbra (NYSE:PEN) stock in their portfolio include Motley Fool Small-Cap Growth ETF (TMFS), MFAM Small-Cap Growth ETF (MFMS), BlackRock Future Health ETF (BMED), ROBO Global Healthcare Technology and Innovation ETF (HTEC), Global X Founder-Run Companies ETF (BOSS), Pacer Lunt MidCap Multi-Factor Alternator ETF (PAMC), Alger Mid Cap 40 ETF (FRTY) and SPDR S&P Health Care Equipment ETF (XHE). What guidance has Penumbra issued on next quarter's earnings? Penumbra issued an update on its FY 2023 earnings guidance on Thursday, February, 23rd. The company provided EPS guidance of for the period. The company issued revenue guidance of $1.00B-, compared to the consensus revenue estimate of $1.00 billion. What is Adam Elsesser's approval rating as Penumbra's CEO? 57 employees have rated Penumbra Chief Executive Officer Adam Elsesser on Glassdoor.com. Adam Elsesser has an approval rating of 88% among the company's employees. What other stocks do shareholders of Penumbra own? Based on aggregate information from My MarketBeat watchlists, some companies that other Penumbra investors own include NVIDIA (NVDA), Intuitive Surgical (ISRG), AbbVie (ABBV), Tesla (TSLA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Netflix (NFLX), UnitedHealth Group (UNH), Boeing (BA) and DexCom (DXCM). What is Penumbra's stock symbol? Penumbra trades on the New York Stock Exchange (NYSE) under the ticker symbol "PEN." Who are Penumbra's major shareholders? Penumbra's stock is owned by many different retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (3.30%), William Blair Investment Management LLC (3.13%), Price T Rowe Associates Inc. MD (2.82%), Clearbridge Investments LLC (2.71%), Geode Capital Management LLC (1.31%) and Norges Bank (1.17%). Insiders that own company stock include Adam Elsesser, Arani Bose, Bridget O'rourke, Don W Kassing, Don W Kassing, Harpreet Grewal, James Robert Pray, Johanna Roberts, Lynn Rothman, Sridhar Kosaraju, Surbhi Sarna and Thomas Wilder. View institutional ownership trends. How do I buy shares of Penumbra? Shares of PEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Penumbra's stock price today? One share of PEN stock can currently be purchased for approximately $274.67. How much money does Penumbra make? Penumbra (NYSE:PEN) has a market capitalization of $10.49 billion and generates $847.13 million in revenue each year. The company earns $-2,000,000.00 in net income (profit) each year or ($0.06) on an earnings per share basis. How many employees does Penumbra have? The company employs 3,900 workers across the globe. How can I contact Penumbra? Penumbra's mailing address is One Penumbra Place, Alameda CA, 94502. The official website for the company is www.penumbrainc.com. The company can be reached via phone at (510) 748-3200, via email at investors@penumbrainc.com, or via fax at 510-748-3232. This page (NYSE:PEN) was last updated on 3/26/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.